Hansa Biopharma interim report Jan-Mar 2021
First commercial sales of Idefirix[®] recorded in Q1; New preclinical collaboration with argenx; Encouraging three-year follow-up data in kidney transplantationLund, Sweden April 22, 2021 Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January – March, 2021. Highlights for the first quarter 2021 · First commercial sales of Idefirix[®] recorded in Q1 2021 following treatment of the first patients. Commercial launch activities in early launch countries continue to be carried